2상모집 중단 (진행 중)

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

연구 개요

The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition

스폰서
협력: 머크(MSD)
적응증
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
중재
Pembrolizumab, Lenvatinib
목표 등록
40
시작일
2021-12-23
완료(예정)
2026-12-23

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.